Please assess the completion status of the following clinical trial:

Trial Title: Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with paroxysmal atrial fibrillation (AF) (recent or new onset) or subjects with persistent AF at the time of randomization~* Subjects who are hemodynamically stable~* Subjects with a low risk of thromboembolic potential~* Subjects who are willing to comply with the reproductive precautions~Exclusion Criteria:~Subjects with:~* History of long QT syndrome, Torsade de Pointes or an uncorrected QT interval of \> 450 ms~* History of myocardial infarction within 6 months of screening~* Acute coronary syndrome, angina or active myocardial ischemia diagnosed by ECG, or other imaging within 6 months of screening~* History of ventricular tachycardia, fibrillation, or resuscitated cardiac arrest~* History of clinically significant congenital heart disease~* Presence of severe aortic or mitral stenosis, aortic or mitral regurgitation, atrial septal defect, or other conditions leading to AF~* Diagnosis of heart failure NYHA Class II-IV or with an ejection fraction \<40% (Part 1 only)~* Diagnosis of heart failure NYHA Class IV or NYHA I, II, or III with an ejection fraction \<35% (Part 2 only)~* Concomitant treatment with class I or III anti-arrhythmics agents unless the medication was discontinued more than 5 half-lives before dosing~* History of seizures~* Diagnosis of atrial flutter~* Diagnosis of stroke, TIA (transient ischemic attack), or any transient neurological deficit within 1 year of screening or known carotid artery stenosis of \>50%~* Cardiac surgery within 3 months of screening~* Bradycardia (\< 50 bpm) or sick sinus syndrome, unless controlled by a pacemaker~* Current reversible cause of AF~* Wolff-Parkinson-White syndrome~* Any congenital abnormality, severe valve disease~* Subjects who have taken another investigational product within 30 days of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Persistent or Paroxysmal AF Part 1: OPC-108459 (Type: EXPERIMENTAL): To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
- Persistent or Paroxysmal AF Part 1: Placebo (Type: PLACEBO_COMPARATOR): None
- Persistent or Paroxysmal AF Part 2: OPC-108459 (Type: EXPERIMENTAL): Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion
- Placebo Part 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).